Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric Disorders
- 1 August 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Psychopharmacology
- Vol. 28 (4), 441-446
- https://doi.org/10.1097/jcp.0b013e31817dd520
Abstract
This multicenter, open-label, sequential-cohort, dose-escalation study explored the tolerability and pharmacokinetics (PK) of aripiprazole up to the maximum approved adult dose (30 mg/d) in children and adolescents (aged 10-17 years) preferentially with primary psychiatric diagnoses of a bipolar or schizophrenia spectrum disorder. During a dose-escalation phase, patients received aripiprazole for up to 12 days using forced titration to achieve doses of 20, 25, or 30 mg/d. In the subsequent fixed-dose phase, patients received the maximum dose for that cohort for an additional 14 days. Tolerability in each fixed-dose cohort was assessed by measures including evaluation of spontaneously reported adverse events (AEs) and vital signs. If 4 of 6 patients tolerated the maximum dose for the cohort, the dose was considered tolerated, and enrollment in the next dose level began. Of 21 enrolled patients, 17 completed the fixed-dose phase. Aripiprazole treatment was generally well tolerated, with criteria for tolerability met for all doses tested. All patients experienced at least 1 AE, none of which met the regulatory criteria for a serious AE. There were no deaths or clinically relevant changes in vital signs or weight. Aripiprazole PK seemed to be linear across the tested dose range and was comparable with previous PK observations in adults. This study provides information regarding the tolerability and PK of aripiprazole up to the maximum adult dose in children and adolescents. These data provided support for exploration of a 30-mg/d dose in child/adolescent schizophrenia and bipolar disorder.This publication has 14 references indexed in Scilit:
- Aripiprazole: pharmacology and evidence in bipolar disorderExpert Opinion on Pharmacotherapy, 2007
- Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapinePsychopharmacology, 2006
- A Randomized, Double-Blind, Placebo-Controlled 26-Week Trial of Aripiprazole in Recently Manic Patients With Bipolar I DisorderBritish Journal of Psychology, 2006
- Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled studyJournal of Psychopharmacology, 2006
- AripiprazoleExpert Opinion on Pharmacotherapy, 2005
- Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy VolunteersThe Journal of Clinical Pharmacology, 2004
- Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trialsSchizophrenia Research, 2003
- Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust PharmacologyNeuropsychopharmacology, 2003
- Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 ReceptorsThe Journal of pharmacology and experimental therapeutics, 2002
- The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptorEuropean Journal of Pharmacology, 2002